# CAND06 — Persistent proteinuria with a monoclonal light-chain abnormality

Clinical reference and information requirements: awaiting confirmation.

Source: https://doi.org/10.3389/fmed.2026.1963349

Decision point: Researcher-defined pretreatment diagnostic review of Case 1 after admission renal/urine and monoclonal-protein data, with tissue biopsy and detailed haematological staging withheld. The source does not timestamp each result.

Opening: A 55-year-old man is admitted on 17 February 2019 after two years of abnormal urinalysis. Persistent proteinuria requires a diagnostic assessment; relevant renal and haematological records can be requested.

Task: Audience: a clinician. Use 180-260 words in English. Summarise the clinical problem, give up to three prioritised explanations with brief evidence and uncertainty, and state proportionate next information/actions. Use only information actually supplied. Do not invent findings, measured values, doses or probabilities. After at most six information-request turns, write a clinician-facing final assessment of 180–260 words. The record system is the information source; the clinical team is the audience. Characterise the renal problem, assess whether monoclonal-protein evidence changes the differential and propose the next discriminating investigations. Do not require a renal pathological subtype before biopsy evidence is released. Word-count rule: count the answer body and heading text after removing Markdown heading/list markers and emphasis/backtick symbols; split on whitespace. Hyphenated expressions count as one word. Exclude JSON only if the task explicitly excludes it. No extra tolerance is added to the stated word range.

## Actual questions and replies

### Question 1
Please provide the renal function results (serum creatinine, eGFR, electrolytes) and the urinalysis/proteinuria data (dipstick, protein:creatinine ratio or 24-hour urine protein, presence of casts or dysmorphic red cells) available at admission.

Saved assessment note: These data define the severity and pattern of the renal problem (nephrotic vs. nephritic range, presence of active sediment) and are essential before considering the differential.

Returned 06.renal_severity (record, presentation): Case 1 admission creatinine was 114 micromol/L and eGFR 61.6 mL/min/1.73 m². Twenty-four-hour urine protein was 1,259 mg and serum albumin 43 g/L. The report describes a two-year history of abnormal urinalysis but supplies no serial pretreatment creatinine trajectory.

Returned 06.electrolytes (record, presentation): Serum calcium was 2.38 mmol/L, phosphate 1.36 mmol/L, potassium 3.7 mmol/L, bicarbonate 22.7 mmol/L and uric acid 300 micromol/L.

Environment feedback: After the two-group reply limit, 06.tubular_markers (the stored urine glucose, pH and low-molecular-weight protein markers) is deferred rather than unavailable. The released renal group already includes the stored 24-hour protein quantity. A total-protein dipstick grade, spot protein:creatinine ratio and urinary-sediment report describing casts or dysmorphic red cells are not supplied in the frozen admission packet; their absence here is not a negative finding or proof that testing was not done. Hidden renal-biopsy cast observations are not urine microscopy and are not released.

### Question 2
Please provide the monoclonal-protein and haematological staging data available at admission: serum protein electrophoresis (SPEP) with any identified M-spike, serum free light chains (kappa, lambda, ratio), serum immunoglobulins (IgG, IgA, IgM), and any haematological markers (full blood count, peripheral smear, beta-2 microglobulin, LDH).

Saved assessment note: The decision point specifies that monoclonal-protein data are part of the pretreatment review. Establishing whether a monoclonal gammopathy is present is critical to distinguishing a plasma-cell or lymphoproliferative-related renal process from a primary glomerular or tubular cause.

Returned 06.immunofixation (record, presentation): Serum immunofixation showed a monoclonal IgG-kappa peak. Detailed marrow, skeletal and renal tissue findings are withheld in this adaptation, rather than being negative.

Returned 06.free_light_chains (record, presentation): Serum free kappa was 427.5 mg/L and free lambda 8.47 mg/L, with kappa/lambda ratio 50.47. Serum IgG was 15.80 g/L. These are Case 1 values.

Environment feedback: The stored monoclonal peak is an immunofixation result, not a supplied quantified SPEP M-spike; no SPEP concentration is provided. After the two-group limit, 06.blood_counts (stored haemoglobin, platelets and LDH) is deferred rather than unavailable. Serum IgA/IgM, a complete blood count, peripheral smear and serum beta-2-microglobulin are not supplied in the frozen packet; missing results do not establish that tests were not performed. The stored urinary beta-2-microglobulin is a different specimen/test and is not substituted for the requested haematological marker. Detailed marrow/cytogenetic and skeletal staging remain deliberately withheld at this decision point.

### Question 3
Please provide the urine protein characterisation data (urine immunofixation or urine protein electrophoresis identifying the protein species in the 24-hour sample) and the stored tubular-function markers (urine glucose, urine pH, and any low-molecular-weight protein measurement such as urinary beta-2-microglobulin or retinol-binding protein).

Saved assessment note: The markedly elevated free kappa (427.5 mg/L, ratio 50.47) with a monoclonal IgG-kappa peak and sub-nephrotic proteinuria (~1.26 g/24 h) with preserved serum albumin (43 g/L) raises the possibility of a tubular rather than glomerular protein-losing mechanism. Urine protein species identification and tubular markers would discriminate between light-chain proximal tubulopathy, light-chain deposition disease, and other glomerular or tubular causes, and would guide whether the renal biopsy is most likely to show tubular versus glomerular pathology.

Returned 06.tubular_markers (record, presentation): Urine glucose was ++ and urine pH 7.5. Urinary beta-2-microglobulin was 30.7 mg/L and alpha-1-microglobulin 110.9 mg/L. The source does not give a simultaneous serum glucose value for interpreting the glycosuria.

Environment feedback: Urine immunofixation or urine protein electrophoresis identifying species in the 24-hour sample is not supplied in the frozen packet. The stored immunofixation result is serum, so it is not substituted for this explicitly urine-specific request. The stored tubular markers are supplied; urinary retinol-binding protein is not reported here. Missing result fields do not establish that those tests were not performed. No additional directly requested stored group is deferred by the two-group limit, and no renal-biopsy result is released.

## Final answer, unchanged

Diagnostic Review – Case 1, Admission 17 Feb 2019

Clinical problem: A 55-year-old man with two years of abnormal urinalysis now has mildly reduced eGFR (61.6), sub-nephrotic proteinuria (1,259 mg/24 h), and preserved serum albumin (43 g/L). Elevated urinary beta-2-microglobulin (30.7 mg/L) and alpha-1-microglobulin (110.9 mg/L) indicate a tubular proteinuric component. Glycosuria (++) without a supplied serum glucose and an alkaline urine pH (7.5) raise the possibility of proximal tubular dysfunction.

Monoclonal-protein evidence: Serum immunofixation identifies an IgG-kappa monoclonal peak; free kappa is 427.5 mg/L (ratio 50.47). This shifts the differential toward a light-chain-mediated renal process.

Prioritised explanations:

1. Monoclonal gammopathy of renal significance (light-chain proximal tubulopathy or deposition disease). Supported by the tubular marker profile and possible proximal dysfunction; uncertain without urine protein electrophoresis or biopsy.

2. Multiple myeloma with renal involvement. Supported by the monoclonal peak and elevated free light chains; uncertain without marrow, skeletal imaging, serum beta-2-microglobulin, or full blood count.

3. Incidental monoclonal gammopathy coexisting with a separate primary renal disease. Cannot be excluded without tissue or urine sediment data.

Next discriminating steps: urine protein electrophoresis/immunofixation; serum beta-2-microglobulin, IgA, IgM, and full blood count; skeletal imaging; and renal biopsy for definitive histological and immunofluorescence characterisation.

## Provisional reference

Represent Case 1 as persistent proteinuria with modestly reduced filtration and strong kappa-restricted monoclonal evidence. Glycosuria and low-molecular-weight protein markers support investigating proximal tubular involvement but do not prove its cause or a complete Fanconi syndrome; simultaneous serum glucose and amino-acid testing are not supplied. A paraprotein-associated renal process is a working concern, while renal biopsy and systemic clonal assessment discriminate among possibilities. Do not import Case 2’s lambda excess, severe renal failure, cast findings or death. Do not require the hidden crystalline subtype, marrow percentage, bone lesions or staging. Exact essentiality and diagnostic recommendations await clinical confirmation.

## Candidate information requirements

- 06.R1 — candidate essential: Request renal function and quantify/characterise the urine abnormality. Why: Persistent abnormal urinalysis and proteinuria require establishing renal severity and whether the pattern suggests glomerular or tubular involvement. Acceptable alternatives: Creatinine/eGFR plus protein quantification and urinalysis or appropriate tubular-protein assessment. Clinically equivalent urine/renal work-up counts; exhaustive tubular testing is not required. Deadline: Before the final assessment, within the six question turns.
- 06.R2 — candidate essential: Request monoclonal-protein testing or an equivalent haematological evaluation. Why: The task explicitly asks whether haematological evidence changes the renal differential; a defensible assessment needs the relevant protein evidence. Acceptable alternatives: Serum/urine electrophoresis with immunofixation and/or serum free light chains, or an appropriate paraprotein work-up. No need to name a hidden renal lesion. Deadline: Before the final assessment, within the six question turns.
- 06.R3 — candidate helpful: Seek evidence of systemic clonal disease and a discriminating tissue/tubular assessment. Why: Monoclonal-protein findings do not by themselves identify the renal lesion or establish the full systemic disease category. Acceptable alternatives: Marrow or skeletal assessment, renal biopsy planning, simultaneous glucose or clinically equivalent proximal-tubular studies. Adequate requests count even when their results are withheld. Deadline: Before the final assessment, within the six question turns.

## Independent ratings

Assess the evidence actually available to the answering model. Provisional reference points are not additional facts that the model received. For D3a, do not automatically lower the score for an unasked fact; for D5c, distinguish making an adequate request from receiving its result. Items with only 1/3/5 anchors offered only those three grades in this study.

| Item | Grade / N/A / Indeterminate | Reason |
|---|---|---|
| D1 Factual accuracy and groundedness | | |
| D3a Problem representation | | |
| D3b Differential Diagnosis Generation | | |
| D5c Context seeking | | |
| D5u Appropriateness of expressed uncertainty | | |

### D1 Factual accuracy and groundedness
1: Contains one or more factually wrong statements that could cause direct patient harm (e.g., wrong drug dose, contraindicated management).
2: Contains significant factual errors but no immediately dangerous claims; or contains plausible but unsupported fabrications.
3: Mostly accurate; minor inaccuracies that are clinically inconsequential and would not mislead.
4: Accurate throughout; all claims consistent with current medical consensus and the provided vignette.
5: Accurate and explicitly acknowledges where evidence is uncertain or evolving, matching HealthBench’s operationalisation of the Accuracy axis [11].

### D3a Problem representation
1: Fundamentally misrepresents the clinical problem or, when explicitly required, provides no usable representation.
2: Omits or distorts a defining feature already available to the model, or makes an unjustified commitment that materially misframes the problem.
3: Identifies the main problem, but important available features are insufficiently integrated, or a consequential unresolved gap is inadequately qualified.
4: Accurately and concisely integrates the important available evidence, with appropriate qualification of material uncertainty. Minor limitations do not change the clinical framing.
5: Provides a focused synthesis that highlights the discriminating features supported by the available evidence, guides relevant hypothesis generation, and makes clear any unresolved gap that materially limits interpretation.

### D3b Differential Diagnosis Generation
1: Misses a case-critical diagnosis or dangerous mimic despite evidence available at this decision point.
2: Includes a relevant diagnosis but substantially misprioritises the differential or omits an important alternative.
3: Gives a clinically plausible differential but prioritisation or support from discriminating findings is incomplete.
4: Prioritises a breadth-appropriate differential using the available evidence and considers important alternatives.
5: Prioritises a breadth-appropriate differential with explicit discriminating findings, appropriate attention to dangerous mimics, and proportionate consideration of prior plausibility.

### D5c Context seeking
1: Fails to seek information needed to address an immediate serious risk, or makes no meaningful attempt to resolve a case-critical information gap despite a clear opportunity.
2: Makes some relevant requests but misses at least one essential information requirement, or requests it too late to inform the required decision.
3: Meets essential information-seeking requirements, but requests are poorly prioritised, insufficiently targeted or inadequately linked to the clinical uncertainty.
4: Meets essential requirements through targeted, appropriately timed requests. Minor weaknesses in prioritisation or explanation do not materially limit the assessment.
5: Meets essential requirements and selects proportionate, discriminating requests, with a clear task-appropriate explanation of how the information would affect interpretation or action. Avoids unnecessary information gathering.

### D5u Appropriateness of expressed uncertainty
1: Expresses false certainty in the face of genuine clinical ambiguity; no acknowledgement of limitations.
2: Hedges generically without engaging with the specific uncertainty.
3: Identifies that uncertainty exists and names its source.
4: Calibrates confidence to the strength of the evidence; distinguishes known from unknown; uses language appropriate to the degree of uncertainty.
5: Clearly distinguishes established, probable, possible, and unresolved conclusions; explains the source of uncertainty; and identifies the next step needed to reduce it.
